Sexually Transmitted Diseases

Perspective gained from persons treated a real-world clinic may help better inform strategies to treat an HIV population that often struggles with viral suppression and consistent care.

A new study from IAS 2021 suggests persons with HIV hospitalized for COVID-19 do not face worse mortality nor major cardiovascular event risk.

The therapy, developed by Lupin Pharmaceuticals, now includes the treatment of trichomoniasis in adults patients and their partners.

More treatment options and modalities are now available for patients.

CDC report highlights disparities among “racial, ethnic, gender, and sexual” minorities.

The prevalence of this disease in this patient population is much higher than in the general public.

A new cohort assessment evidences a disparity in weight-related outcomes with the ART regimens at 18 months.

A comparative study of same-day and seven-day TB test results show there is little difference in HIV treatment adherence or outcomes at 48 weeks.

Phase 1/2 trial results showed the immunomodulary vaccine regimen could induce significant T-cell response in patients with HIV.

New research from the Emerman Lab at Fred Hutchinson shows potential for advancing HIV-1 life cycle understanding.

Presented at CROI, investigators have identified sex-modified inflammatory predictors of cardiovascular and VTE risks among patients with HIV.

A talk on optimistic, but pragmatic hopes for HIV cure and vaccine research, led by federal-level experts.

Attention to the endemic virus has lessened over years, and screening and prevention access remains limited among the most at-risk groups.

A John Hopkins expert and major study leader details the evolving epidemiology of the virus.

The cabotegravir and rilpivirine formulation was approved on the basis of 2 trials assessing its viral suppression capability in 1100-plus adults with HIV.

The U.S. sentinel surveillance program is a project which monitors for antibiotic-resistant gonorrhea.

In testing, fingolimod blocked cell-free and cell-to-cell transmission of HIV, reducing latent virus.

Study explores the antiviral mechanisms of C19orf66, an interferon-induced inhibitor.

Conversations about PrEP with a clinician are the least common among adolescents with the greatest risk for HIV.

A hospital case series of patients with both COVID-19 and HIV describes recovery, but highlights the need to refine treatment.

The CDC is calling for all adults to get tested for hepatitis C after the annual rate of infections tripled between 2009 and 2019.

The 2 new recommendations are for HCV screening at least once for all adults aged 18 years or older and HCV screening for women during each pregnancy.

HIV training pathways in residency have added 90 HIV physicians to the workforce since 2006.

Funded jurisdictions scramble to meet daunting deadlines yet maintain optimism that the new federal initiative can end flat funding and catalyze progress.

When drug resistance means ART options are exhausted, HIV patients need newer choices. A new study shows that novel prodrug fostemsavir is an effective alternative.

With advancements in antiretroviral therapy, people with HIV are now living longer and developing age-related chronic conditions.